Spyre Therapeutics Stock Falls 14% Following Larger-Than-Expected Equity Offering at Discount to Market Price

Spyre Therapeutics raised $350 million through a stock offering at $85 per share, approximately 8% below Monday's closing price, with shares declining 14% following the announcement. The offering was upsized from an originally planned $250 million, adding roughly 5% additional dilution to shareholders. The proceeds bring Spyre's cash position to approximately $1.5 billion, which will fund Phase 3 clinical trial preparations across its gastroenterology, rheumatology, and dermatology programs.

Spyre Therapeutics has significantly expanded its equity base over recent years as a means of funding drug development. The company's diluted share count grew roughly ninefold between 2023 and 2024, reflecting the capital-intensive nature of bringing therapies through clinical trials. This latest offering represents approximately 5% additional dilution, though investors absorbed a steeper price concession—the $85 pricing marked an 8% discount to the previous trading level, suggesting underwriters needed to offer meaningful incentives to move the larger-than-expected deal size.

The company currently has no approved medications generating revenue, making cash reserves critical to survival. With roughly $1.5 billion now on hand following this raise, Spyre has sufficient runway to advance multiple late-stage programs spanning gastroenterology, rheumatology, and dermatology indications. The success or failure of these Phase 3 trials will ultimately determine whether the capital raised today translates into shareholder value or becomes sunk development costs.